Pre-made Inebilizumab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-273-1mg	1mg	3090
GMP-Bios-ab-273-10mg	10mg	Inquiry
GMP-Bios-ab-273-100mg	100mg	Inquiry
GMP-Bios-ab-273-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name	Inebilizumab
Target	CD19
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Cellective Therapeutics;MedImmune
Conditions Approved	Neuromyelitis optica
Conditions Active	Autoimmune disorders;Myasthenia gravis;Renal transplant rejection
Conditions Discontinued	B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma
Development Tech	POTELLIGENT Technology